360° SearchNetwork Hot Spots Trends Time Series

Cangene Corp

Type: Company

Name: Cangene Corp

First reported May 16 2013 - Updated May 16 2013 - 2 reports

Victims of tainted blood scandal urging governments to stop plasma clinics

TORONTO ? Victims of the tainted blood scandal and their families are urging the Ontario and federal governments to stop proposed blood-plasma clinics from operating in the province.Canada could face another blood tragedy unless the two governments refuse ... [Published News 1130 - May 16 2013]

Entities: Health Canada, Deb Matthews, Blood Plasma

First reported May 01 2013 - Updated May 01 2013 - 1 reports

Product showcase, May 2013

New approvals FDA has approved Cangene’s botulism antitoxin heptavalent (A, B, C, D, E, F, G)-(equine) to treat patients showing signs of botulism following documented or suspected exposure to botulinum neurotoxin. The product is derived from horse plasma ... [Published Pharmacist.com - May 01 2013]

Entities: Botulism, Cangene Corp, Antitoxin, Neurotoxin

First reported Mar 14 2013 - Updated Mar 14 2013 - 1 reports

Cangene loses $3.26-million (U.S.) in Q2 fiscal 2013

Cangene Corp. has released its financial results for the second quarter of 2013, which ended on Jan. 31, 2013. (Information and non-IFRS Financial Measures at the end of this release. Unless noted otherwise, all dollar amounts are in U.S. dollars.) Total ... [Published Stockwatch - Mar 14 2013]

Entities: Cangene Corp, Chicken Pox, Recombinant

First reported Feb 28 2013 - Updated Feb 28 2013 - 1 reports

Centers for Disease Control and Prevention

Cangene to continue using FFF as Varizig distributor

FFF Enterprises Inc. will remain the exclusive distributor for Varizig (varicella zoster immune globulin (human)), a hyperimmune manufactured by Cangene Corp. VARIZIG is indicated for post-exposure prophylaxis of varicella (chickenpox) in high-risk patient ... [Published Stockwatch - Feb 28 2013]

Entities: Cangene Corp, Chicken Pox, Immunoglobulin, Virus, Centers for Disease Control and Prevention

First reported Feb 25 2013 - Updated Feb 25 2013 - 1 reports

Toronto stock exchange

Monday Deal Review: February 25, 2013

Welcome to your Monday Biotech Deal Review for February 25, 2013! This week saw significant activity on the investment front. Stem Cell Therepeutics and Sirona have each indicated an intention to raise funds through private placements, while Oncolytics ... [Published The Cross-Border Biotech Blog - Feb 25 2013]

Entities: Amorfix Life Sciences Ltd, Toronto stock exchange, Sernova Corp, Shigamabs

First reported Feb 22 2013 - Updated Feb 22 2013 - 1 reports

University of British Columbia

Cangene licenses Alzheimer's technology from UBC

A truly made-in-Canada treatment for one of the world's most devastating diseases could be closer to patients thanks to a new technology targeting Alzheimer's disease developed at the University of British Columbia (UBC) and licensed to Cangene Corp. ... [Published Stockwatch - Feb 22 2013]

Entities: Cangene Corp, Alzheimer's Disease, degenerative disease, CASHMAN, University of British Columbia

First reported Feb 20 2013 - Updated Feb 20 2013 - 1 reports

Cangene closes hemophilia compound acquisition

Cangene Corp. has closed the acquisition of the investigational hemophilia compound IB1001 and certain other assets from Ipsen and Inspiration Biopharmaceuticals Inc. in connection with Inspiration's bankruptcy proceedings. (Unless noted otherwise, all ... [Published Stockwatch - Feb 20 2013]

Entities: Cangene Corp, Hemophilia, Hemophilia B, Recombinant, Acquisition

First reported Feb 20 2013 - Updated Feb 20 2013 - 1 reports

Cangene Announces Closing Of Acquisition Of Late Stage Hemophilia B Product

Sorry, there is a problem with our siteThe page you have requested cannot be displayedThis occurrence has been logged for quality assurance purposes. ... [Published Bioresearch Online - Feb 20 2013]

Entities: Cangene Corp, Hemophilia B, Acquisition

First reported Feb 13 2013 - Updated Feb 13 2013 - 1 reports

Cangene equine botulism antitoxin receives FDA support

The U.S. Food and Drug Administration blood products advisory committee has voted unanimously in support of the questions posed by the FDA on Cangene Corp.'s botulism antitoxin (equine) heptavalent (A, B, C, D, E, F and G) in that there is a likely clinical ... [Published Stockwatch - Feb 13 2013]

Entities: Cangene Corp, Botulism, Antitoxin, Equine

First reported Feb 11 2013 - Updated Feb 11 2013 - 1 reports

Monday Deal Review: February 11, 2013

Welcome to your Monday Biotech Deal Review for February 11, 2013! This week saw YM Biosciences obtain the required court approval necessary before their plan of arrangement acquisition by Gilead could proceed. The transaction is essentially free to ... [Published The Cross-Border Biotech Blog - Feb 11 2013]

Entities: Trillium, Cangene Corp, Common Shares, Toronto stock exchange, Private Placement

First reported Feb 08 2013 - Updated Feb 08 2013 - 1 reports

DOTW: Biogen Puts Offshore Cash to Work

When it comes to corporate tax planning, biopharmas as a group aren’t spectacularly sophisticated. (A few exceptions come to mind, most notably specialty pharma Valeant and Bristol Myers-Squibb, the latter of which upped its game and expects to drop ... [Published The IN VIVO Blog - Feb 08 2013]

Entities: Tysabri, Aurinia, Ipsen SA, Alnylam Pharmaceuticals Inc

First reported Feb 08 2013 - Updated Feb 08 2013 - 1 reports

Cangene's Antidote for Terrorism Toxin Works, FDA Staff Says - Bloomberg

Cangene's Antidote for Terrorism Toxin Works, FDA Staff Says Bloomberg Cangene Corp.'s animal studies on an experimental antidote for a toxin considered a bioterrorism threat are sufficient enough to suggest the treatment will work in humans, U.S. ... [Published Bloomberg via Google News - Feb 08 2013]

Entities: Cangene Corp, Antidote, Toxin

Quotes

...our net earnings on a year-to-date basis, and by our recent licensing agreements and acquisitions," says John Sedor, President and CEO of Cangene. "We are excited about IB1001, the late-stage intravenous recombinant Factor IX product we acquired in February, as well as our recent licensing agreement for technology to advance a potential treatment for Alzheimer's Disease. We remain focused on adding to our product portfolio to maximize the full potential of our exceptional commercial platform, and to diversify and strengthen our revenue streams. We believe Cangene is on the right path to delivering significant long-term value to shareholders." As at January 31, 2013, Cangene had no debt and a cash balance of $38.7 million, compared with no debt and a cash balance of $35...

Cangene loses $3.26-million (U.S.) in Q2 fiscal 2013 [Published Stockwatch - Mar 14 2013]

Cangene president and CEO John Sedor said, "Cangene will continue to pursue opportunities to leverage our core competencies in biodefence while maintaining a focus on our commercial product business and expanding our pipeline." As part of the new contract with the Centers for Disease Control and Prevention, Cangene will supply Vaccinia Immune Globulin Intravenous (VIGIV) into...

Cangene extends biodefence contracts with US [Published Pharmaceutical Business Review - Aug 29 2012]

The World Health Organization (WHO) definition of sexual health; "the state of physical, emotional, mental and social well-being related to sexuality; it is not merely the absence of disease, d..."

HIV in Persons Born Outside the United States 20072010 HIV in Persons Born Outside the United States [Published BioPortfolio - Aug 08 2012]

More Content

sort by: Date \| Relevance
Victims of tainted blood scandal urging governm... [Published News 1130 - May 16 2013]
Victims of tainted blood scandal urging governm... [Published Kelowna Daily Courier - May 16 2013]
Product showcase, May 2013 [Published Pharmacist.com - May 01 2013]
Clostridium Infections - Pipeline Review, H1 2013 [Published PredictWallStreet - Apr 15 2013]
Positive Share Price Performance in Q1 2013 for... [Published The Cross-Border Biotech Blog - Apr 11 2013]
Cangene loses $3.26-million (U.S.) in Q2 fiscal... [Published Stockwatch - Mar 14 2013]
Vaccinia: Lending a new terror to sex [Published H5N1 - Mar 01 2013]
Cangene to continue using FFF as Varizig distri... [Published Stockwatch - Feb 28 2013]
FFF Enterprises Named Exclusive Distributor of ... [Published Marketwire - Breaking News Releases - Feb 28 2013]
Ipsen's 2012 Results and 2013 Financial Objecti... [Published Yahoo! Finance - Feb 27 2013]
Monday Deal Review: February 25, 2013 [Published The Cross-Border Biotech Blog - Feb 25 2013]
Cangene licenses Alzheimer's technology from UBC [Published Stockwatch - Feb 22 2013]
Cangene Announces Closing Of Acquisition Of Lat... [Published Bioresearch Online - Feb 20 2013]
Cangene closes hemophilia compound acquisition [Published Stockwatch - Feb 20 2013]
Inspiration Biopharmaceuticals and Ipsen Announ... [Published EON Health & Medicine - Feb 20 2013]
Inspiration Biopharmaceuticals and Ipsen Announ... [Published Business Wire Health News - Feb 20 2013]
Ipsen and Inspiration Biopharmaceuticals Announ... [Published Business Wire Health News - Feb 20 2013]
Cangene equine botulism antitoxin receives FDA ... [Published Stockwatch - Feb 13 2013]
Monday Deal Review: February 11, 2013 [Published The Cross-Border Biotech Blog - Feb 11 2013]
DOTW: Biogen Puts Offshore Cash to Work [Published The IN VIVO Blog - Feb 08 2013]
Cangene's Antidote for Terrorism Toxin Works, F... [Published Bloomberg via Google News - Feb 08 2013]
Celtic Pharma Welcomes the Results of the Sale ... [Published EON Health & Medicine - Feb 07 2013]
Celtic Pharma Welcomes the Results of the Sale ... [Published EON Business - Feb 07 2013]
Celtic Pharma Welcomes the Results of the Sale ... [Published Business Wire Health News - Feb 07 2013]
Inspiration Biopharmaceuticals and Ipsen Comple... [Published EON Health & Medicine - Feb 06 2013]
Inspiration Biopharmaceuticals and Ipsen Comple... [Published Business Wire Professional Services News - Feb 06 2013]
Inspiration Biopharmaceuticals and Ipsen Comple... [Published Business Wire Health News - Feb 06 2013]
Ipsen and Inspiration Biopharmaceuticals enter ... [Published Business Wire Health News - Feb 06 2013]
Miraculins Named Manitoba Life Science Company ... [Published Marketwire - Breaking News Releases - Feb 04 2013]
Upcoming AdComm Topics [Published Eye on FDA - Jan 28 2013]

Blogs

sort by: Date \| Relevance
Positive Share Price Performance in Q1 2013 for... [Published The Cross-Border Biotech Blog - Apr 11 2013] In order to assess share price performance among the Canadian public healthcare companies, I have selected a portfolio of 118 companies for the 2013 assessment. The portfolio has been split into three parts according to the closing share price on ...
Vaccinia: Lending a new terror to sex [Published H5N1 - Mar 01 2013] As if I didn't have enough to worry about, Twitter and CIDRAP have been talking about something called vaccinia. A quick Google search took me to this March 1 Morbidity and Mortality Weekly Report: Secondary and Tertiary Transmission of Vaccinia Virus ...
Monday Deal Review: February 25, 2013 [Published The Cross-Border Biotech Blog - Feb 25 2013] Welcome to your Monday Biotech Deal Review for February 25, 2013! This week saw significant activity on the investment front. Stem Cell Therepeutics and Sirona have each indicated an intention to raise funds through private placements, while Oncolytics ...
Monday Deal Review: February 11, 2013 [Published The Cross-Border Biotech Blog - Feb 11 2013] Welcome to your Monday Biotech Deal Review for February 11, 2013! This week saw YM Biosciences obtain the required court approval necessary before their plan of arrangement acquisition by Gilead could proceed. The transaction is essentially free to ...
DOTW: Biogen Puts Offshore Cash to Work [Published The IN VIVO Blog - Feb 08 2013] When it comes to corporate tax planning, biopharmas as a group aren’t spectacularly sophisticated. (A few exceptions come to mind, most notably specialty pharma Valeant and Bristol Myers-Squibb, the latter of which upped its game and expects to drop ...

Press Releases

sort by: Date \| Relevance
FFF Enterprises Named Exclusive Distributor of ... [Published Marketwire - Breaking News Releases - Feb 28 2013]
Inspiration Biopharmaceuticals and Ipsen Announ... [Published EON Health & Medicine - Feb 20 2013]
Inspiration Biopharmaceuticals and Ipsen Announ... [Published Business Wire Health News - Feb 20 2013]
Ipsen and Inspiration Biopharmaceuticals Announ... [Published Business Wire Health News - Feb 20 2013]
Celtic Pharma Welcomes the Results of the Sale ... [Published EON Health & Medicine - Feb 07 2013]